Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Nestle invests in microbiome-based diagnostics venture

The Nestle logo is pictured on the company headquarters entrance building in Vevey, Switzerland February 18, 2016. REUTERS/Pierre Albouy/File Photo

ZURICH (Reuters) - Food group Nestle's <NESN.S> health science business is investing 20 million euros ($22.8 million) in a joint venture with pharma and diagnostics company Enterome SA to develop microbiome-based diagnostics for inflammatory bowel and liver diseases, Enterome said on Tuesday.

This is the latest in a string of investments by Nestle Health Science targeting gastrointestinal health, and comes as the world's biggest food group is targeted by activist investor Daniel Loeb who is pressing for improved returns.

The new company, Microbiome Diagnostics Partners, will be a 50/50 joint venture, with Enterome contributing its current microbiome diagnostic programs and intellectual property and Nestle's Prometheus Laboratories contributing its diagnostics development and commercial expertise, Enterome said.

(Reporting by Silke Koltrowitz)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.